Solazyme Inc (SZYM): The Outlook You Should See

Page 2 of 2

In other news, each of the three commercial biorefineries under construction remains on track.

Biorefinery Nameplate Capacity Commissioning Product By…
Peoria (product development) 8,000 metric tons Active (test quantities)
Solazyme Roquette Nutritionals 5,000 metric tons June 2013 2H13
Solazyme Bunge 100,000 metric tons 2H13 4Q13
ADM/Clinton 20,000 metric tons Early 2014 Early 2014

Source: Solazyme

The following updates were also provided by management:

The Algenist product portfolio launched two new products and expanded into Turkey. Further expansion is expected into Mexico and Asia soon, with sales predicted to pick up in the second quarter.

Levels of myristic acid, one of the highest-value oils targeted by the company with partner Mitsui, reached levels of 60% in the company’s myristic oil profile. That is 400% greater than levels found in coconut oil, the traditional source of myristic acid.

Foolish bottom line
There is much work to be done to de-risk Solazyme Inc (NASDAQ:SZYM)’s technology. However, the company’s strong financial position and commitment to execution could bolster the argument for an investment. Solazyme had a quiet quarter, but made progress where it counts. The company remains on track with commercial progress on the construction side and product development side. Investors should not rock the boat one way or the other from an investment strategy perspective — just stick to your plan.

The article Solazyme Adds (More) Precision to Tailored Oil Platform originally appeared on Fool.com.

Motley Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and emerging technologies.The Motley Fool owns shares of Solazyme.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Page 2 of 2